nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—AGTR1—pancreatic cancer	0.56	1	CbGaD
Valsartan—SLCO1B3—Docetaxel—pancreatic cancer	0.077	0.273	CbGbCtD
Valsartan—SLCO1B1—Irinotecan—pancreatic cancer	0.0612	0.217	CbGbCtD
Valsartan—ALB—Erlotinib—pancreatic cancer	0.0371	0.132	CbGbCtD
Valsartan—ALB—Irinotecan—pancreatic cancer	0.0335	0.119	CbGbCtD
Valsartan—ALB—Fluorouracil—pancreatic cancer	0.0322	0.114	CbGbCtD
Valsartan—CYP2C9—Tamoxifen—pancreatic cancer	0.0235	0.0835	CbGbCtD
Valsartan—CYP2C9—Fluorouracil—pancreatic cancer	0.0173	0.0615	CbGbCtD
Valsartan—Forasartan—AGTR1—pancreatic cancer	0.00186	0.315	CrCbGaD
Valsartan—Tasosartan—AGTR1—pancreatic cancer	0.00113	0.191	CrCbGaD
Valsartan—Olmesartan—AGTR1—pancreatic cancer	0.000951	0.162	CrCbGaD
Valsartan—Candesartan—AGTR1—pancreatic cancer	0.00074	0.126	CrCbGaD
Valsartan—Irbesartan—AGTR1—pancreatic cancer	0.00074	0.126	CrCbGaD
Valsartan—Losartan—AGTR1—pancreatic cancer	0.000477	0.0809	CrCbGaD
Valsartan—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000152	0.00125	CcSEcCtD
Valsartan—Insomnia—Fluorouracil—pancreatic cancer	0.000152	0.00125	CcSEcCtD
Valsartan—Somnolence—Gemcitabine—pancreatic cancer	0.000152	0.00125	CcSEcCtD
Valsartan—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000152	0.00125	CcSEcCtD
Valsartan—Fatigue—Irinotecan—pancreatic cancer	0.000152	0.00124	CcSEcCtD
Valsartan—Paraesthesia—Fluorouracil—pancreatic cancer	0.000151	0.00124	CcSEcCtD
Valsartan—Alopecia—Docetaxel—pancreatic cancer	0.000151	0.00124	CcSEcCtD
Valsartan—Pruritus—Sunitinib—pancreatic cancer	0.000151	0.00124	CcSEcCtD
Valsartan—Constipation—Irinotecan—pancreatic cancer	0.00015	0.00123	CcSEcCtD
Valsartan—Dyspnoea—Fluorouracil—pancreatic cancer	0.00015	0.00123	CcSEcCtD
Valsartan—Mental disorder—Docetaxel—pancreatic cancer	0.00015	0.00123	CcSEcCtD
Valsartan—Somnolence—Fluorouracil—pancreatic cancer	0.00015	0.00123	CcSEcCtD
Valsartan—Malnutrition—Docetaxel—pancreatic cancer	0.000149	0.00122	CcSEcCtD
Valsartan—Decreased appetite—Gemcitabine—pancreatic cancer	0.000149	0.00122	CcSEcCtD
Valsartan—Dyspepsia—Fluorouracil—pancreatic cancer	0.000148	0.00122	CcSEcCtD
Valsartan—Nausea—Tamoxifen—pancreatic cancer	0.000148	0.00121	CcSEcCtD
Valsartan—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000148	0.00121	CcSEcCtD
Valsartan—Fatigue—Gemcitabine—pancreatic cancer	0.000148	0.00121	CcSEcCtD
Valsartan—Muscular weakness—Epirubicin—pancreatic cancer	0.000147	0.00121	CcSEcCtD
Valsartan—Constipation—Gemcitabine—pancreatic cancer	0.000146	0.0012	CcSEcCtD
Valsartan—Nausea—Erlotinib—pancreatic cancer	0.000146	0.0012	CcSEcCtD
Valsartan—Decreased appetite—Fluorouracil—pancreatic cancer	0.000146	0.0012	CcSEcCtD
Valsartan—Diarrhoea—Sunitinib—pancreatic cancer	0.000146	0.0012	CcSEcCtD
Valsartan—Dysgeusia—Docetaxel—pancreatic cancer	0.000146	0.0012	CcSEcCtD
Valsartan—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000145	0.00119	CcSEcCtD
Valsartan—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000145	0.00119	CcSEcCtD
Valsartan—Back pain—Docetaxel—pancreatic cancer	0.000144	0.00118	CcSEcCtD
Valsartan—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000144	0.00118	CcSEcCtD
Valsartan—Muscle spasms—Docetaxel—pancreatic cancer	0.000143	0.00117	CcSEcCtD
Valsartan—Dizziness—Sunitinib—pancreatic cancer	0.000141	0.00116	CcSEcCtD
Valsartan—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000141	0.00116	CcSEcCtD
Valsartan—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000141	0.00116	CcSEcCtD
Valsartan—Abdominal pain—Irinotecan—pancreatic cancer	0.000139	0.00114	CcSEcCtD
Valsartan—Bronchitis—Epirubicin—pancreatic cancer	0.000139	0.00114	CcSEcCtD
Valsartan—Muscular weakness—Doxorubicin—pancreatic cancer	0.000136	0.00112	CcSEcCtD
Valsartan—Vomiting—Sunitinib—pancreatic cancer	0.000136	0.00111	CcSEcCtD
Valsartan—Neutropenia—Epirubicin—pancreatic cancer	0.000135	0.00111	CcSEcCtD
Valsartan—Rash—Sunitinib—pancreatic cancer	0.000135	0.0011	CcSEcCtD
Valsartan—Dermatitis—Sunitinib—pancreatic cancer	0.000134	0.0011	CcSEcCtD
Valsartan—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000134	0.0011	CcSEcCtD
Valsartan—Urticaria—Fluorouracil—pancreatic cancer	0.000134	0.0011	CcSEcCtD
Valsartan—Headache—Sunitinib—pancreatic cancer	0.000134	0.0011	CcSEcCtD
Valsartan—Syncope—Docetaxel—pancreatic cancer	0.000133	0.0011	CcSEcCtD
Valsartan—Palpitations—Docetaxel—pancreatic cancer	0.000132	0.00108	CcSEcCtD
Valsartan—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000132	0.00108	CcSEcCtD
Valsartan—Loss of consciousness—Docetaxel—pancreatic cancer	0.000131	0.00107	CcSEcCtD
Valsartan—Cough—Docetaxel—pancreatic cancer	0.00013	0.00107	CcSEcCtD
Valsartan—Hypersensitivity—Irinotecan—pancreatic cancer	0.000129	0.00106	CcSEcCtD
Valsartan—Infestation NOS—Epirubicin—pancreatic cancer	0.000128	0.00105	CcSEcCtD
Valsartan—Infestation—Epirubicin—pancreatic cancer	0.000128	0.00105	CcSEcCtD
Valsartan—Bronchitis—Doxorubicin—pancreatic cancer	0.000128	0.00105	CcSEcCtD
Valsartan—Myalgia—Docetaxel—pancreatic cancer	0.000127	0.00104	CcSEcCtD
Valsartan—Arthralgia—Docetaxel—pancreatic cancer	0.000127	0.00104	CcSEcCtD
Valsartan—Chest pain—Docetaxel—pancreatic cancer	0.000127	0.00104	CcSEcCtD
Valsartan—Nausea—Sunitinib—pancreatic cancer	0.000127	0.00104	CcSEcCtD
Valsartan—Renal failure—Epirubicin—pancreatic cancer	0.000126	0.00104	CcSEcCtD
Valsartan—Asthenia—Irinotecan—pancreatic cancer	0.000126	0.00103	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000126	0.00103	CcSEcCtD
Valsartan—Neutropenia—Doxorubicin—pancreatic cancer	0.000125	0.00102	CcSEcCtD
Valsartan—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000124	0.00102	CcSEcCtD
Valsartan—Dry mouth—Docetaxel—pancreatic cancer	0.000124	0.00102	CcSEcCtD
Valsartan—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000124	0.00102	CcSEcCtD
Valsartan—Asthenia—Gemcitabine—pancreatic cancer	0.000123	0.00101	CcSEcCtD
Valsartan—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000122	0.000999	CcSEcCtD
Valsartan—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000121	0.000997	CcSEcCtD
Valsartan—Oedema—Docetaxel—pancreatic cancer	0.000121	0.000997	CcSEcCtD
Valsartan—Epistaxis—Epirubicin—pancreatic cancer	0.000121	0.000995	CcSEcCtD
Valsartan—Pruritus—Gemcitabine—pancreatic cancer	0.000121	0.000994	CcSEcCtD
Valsartan—Infection—Docetaxel—pancreatic cancer	0.000121	0.000991	CcSEcCtD
Valsartan—Sinusitis—Epirubicin—pancreatic cancer	0.000121	0.000989	CcSEcCtD
Valsartan—Diarrhoea—Irinotecan—pancreatic cancer	0.00012	0.000987	CcSEcCtD
Valsartan—Shock—Docetaxel—pancreatic cancer	0.00012	0.000981	CcSEcCtD
Valsartan—Nervous system disorder—Docetaxel—pancreatic cancer	0.000119	0.000978	CcSEcCtD
Valsartan—Pruritus—Fluorouracil—pancreatic cancer	0.000119	0.000977	CcSEcCtD
Valsartan—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000119	0.000976	CcSEcCtD
Valsartan—Infestation NOS—Doxorubicin—pancreatic cancer	0.000119	0.000976	CcSEcCtD
Valsartan—Infestation—Doxorubicin—pancreatic cancer	0.000119	0.000976	CcSEcCtD
Valsartan—Skin disorder—Docetaxel—pancreatic cancer	0.000118	0.000969	CcSEcCtD
Valsartan—Diarrhoea—Gemcitabine—pancreatic cancer	0.000117	0.000961	CcSEcCtD
Valsartan—Renal failure—Doxorubicin—pancreatic cancer	0.000117	0.000959	CcSEcCtD
Valsartan—Dizziness—Irinotecan—pancreatic cancer	0.000116	0.000954	CcSEcCtD
Valsartan—Haemoglobin—Epirubicin—pancreatic cancer	0.000116	0.000951	CcSEcCtD
Valsartan—Anorexia—Docetaxel—pancreatic cancer	0.000116	0.00095	CcSEcCtD
Valsartan—Rhinitis—Epirubicin—pancreatic cancer	0.000116	0.000949	CcSEcCtD
Valsartan—Haemorrhage—Epirubicin—pancreatic cancer	0.000115	0.000947	CcSEcCtD
Valsartan—Hepatitis—Epirubicin—pancreatic cancer	0.000115	0.000947	CcSEcCtD
Valsartan—Diarrhoea—Fluorouracil—pancreatic cancer	0.000115	0.000945	CcSEcCtD
Valsartan—Pharyngitis—Epirubicin—pancreatic cancer	0.000114	0.00094	CcSEcCtD
Valsartan—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000114	0.000935	CcSEcCtD
Valsartan—Hypotension—Docetaxel—pancreatic cancer	0.000114	0.000932	CcSEcCtD
Valsartan—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000113	0.00093	CcSEcCtD
Valsartan—Urethral disorder—Epirubicin—pancreatic cancer	0.000113	0.000928	CcSEcCtD
Valsartan—Epistaxis—Doxorubicin—pancreatic cancer	0.000112	0.00092	CcSEcCtD
Valsartan—Vomiting—Irinotecan—pancreatic cancer	0.000112	0.000917	CcSEcCtD
Valsartan—Sinusitis—Doxorubicin—pancreatic cancer	0.000112	0.000915	CcSEcCtD
Valsartan—Dizziness—Fluorouracil—pancreatic cancer	0.000111	0.000914	CcSEcCtD
Valsartan—Rash—Irinotecan—pancreatic cancer	0.000111	0.000909	CcSEcCtD
Valsartan—Dermatitis—Irinotecan—pancreatic cancer	0.000111	0.000909	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000111	0.000908	CcSEcCtD
Valsartan—Headache—Irinotecan—pancreatic cancer	0.00011	0.000904	CcSEcCtD
Valsartan—Insomnia—Docetaxel—pancreatic cancer	0.00011	0.000902	CcSEcCtD
Valsartan—Paraesthesia—Docetaxel—pancreatic cancer	0.000109	0.000895	CcSEcCtD
Valsartan—Vomiting—Gemcitabine—pancreatic cancer	0.000109	0.000893	CcSEcCtD
Valsartan—Dyspnoea—Docetaxel—pancreatic cancer	0.000108	0.000889	CcSEcCtD
Valsartan—Somnolence—Docetaxel—pancreatic cancer	0.000108	0.000886	CcSEcCtD
Valsartan—Rash—Gemcitabine—pancreatic cancer	0.000108	0.000886	CcSEcCtD
Valsartan—Dermatitis—Gemcitabine—pancreatic cancer	0.000108	0.000885	CcSEcCtD
Valsartan—Haemoglobin—Doxorubicin—pancreatic cancer	0.000107	0.00088	CcSEcCtD
Valsartan—Headache—Gemcitabine—pancreatic cancer	0.000107	0.00088	CcSEcCtD
Valsartan—Cardiac disorder—Epirubicin—pancreatic cancer	0.000107	0.000879	CcSEcCtD
Valsartan—Vomiting—Fluorouracil—pancreatic cancer	0.000107	0.000878	CcSEcCtD
Valsartan—Rhinitis—Doxorubicin—pancreatic cancer	0.000107	0.000878	CcSEcCtD
Valsartan—Dyspepsia—Docetaxel—pancreatic cancer	0.000107	0.000878	CcSEcCtD
Valsartan—Hepatitis—Doxorubicin—pancreatic cancer	0.000107	0.000876	CcSEcCtD
Valsartan—Haemorrhage—Doxorubicin—pancreatic cancer	0.000107	0.000876	CcSEcCtD
Valsartan—Rash—Fluorouracil—pancreatic cancer	0.000106	0.000871	CcSEcCtD
Valsartan—Dermatitis—Fluorouracil—pancreatic cancer	0.000106	0.00087	CcSEcCtD
Valsartan—Pharyngitis—Doxorubicin—pancreatic cancer	0.000106	0.000869	CcSEcCtD
Valsartan—Decreased appetite—Docetaxel—pancreatic cancer	0.000106	0.000867	CcSEcCtD
Valsartan—Headache—Fluorouracil—pancreatic cancer	0.000105	0.000865	CcSEcCtD
Valsartan—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000105	0.000865	CcSEcCtD
Valsartan—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000105	0.000861	CcSEcCtD
Valsartan—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000105	0.000861	CcSEcCtD
Valsartan—Fatigue—Docetaxel—pancreatic cancer	0.000105	0.00086	CcSEcCtD
Valsartan—Angiopathy—Epirubicin—pancreatic cancer	0.000105	0.000859	CcSEcCtD
Valsartan—Urethral disorder—Doxorubicin—pancreatic cancer	0.000105	0.000859	CcSEcCtD
Valsartan—Nausea—Irinotecan—pancreatic cancer	0.000104	0.000857	CcSEcCtD
Valsartan—Immune system disorder—Epirubicin—pancreatic cancer	0.000104	0.000855	CcSEcCtD
Valsartan—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000104	0.000853	CcSEcCtD
Valsartan—Constipation—Docetaxel—pancreatic cancer	0.000104	0.000853	CcSEcCtD
Valsartan—Alopecia—Epirubicin—pancreatic cancer	0.000102	0.000837	CcSEcCtD
Valsartan—Nausea—Gemcitabine—pancreatic cancer	0.000102	0.000835	CcSEcCtD
Valsartan—Mental disorder—Epirubicin—pancreatic cancer	0.000101	0.000829	CcSEcCtD
Valsartan—Malnutrition—Epirubicin—pancreatic cancer	0.0001	0.000824	CcSEcCtD
Valsartan—Nausea—Fluorouracil—pancreatic cancer	0.0001	0.000821	CcSEcCtD
Valsartan—Gastrointestinal pain—Docetaxel—pancreatic cancer	9.93e-05	0.000815	CcSEcCtD
Valsartan—Cardiac disorder—Doxorubicin—pancreatic cancer	9.9e-05	0.000813	CcSEcCtD
Valsartan—Flatulence—Epirubicin—pancreatic cancer	9.89e-05	0.000812	CcSEcCtD
Valsartan—Dysgeusia—Epirubicin—pancreatic cancer	9.83e-05	0.000807	CcSEcCtD
Valsartan—Back pain—Epirubicin—pancreatic cancer	9.71e-05	0.000797	CcSEcCtD
Valsartan—Angiopathy—Doxorubicin—pancreatic cancer	9.68e-05	0.000795	CcSEcCtD
Valsartan—Muscle spasms—Epirubicin—pancreatic cancer	9.65e-05	0.000792	CcSEcCtD
Valsartan—Immune system disorder—Doxorubicin—pancreatic cancer	9.64e-05	0.000791	CcSEcCtD
Valsartan—Mediastinal disorder—Doxorubicin—pancreatic cancer	9.62e-05	0.000789	CcSEcCtD
Valsartan—Abdominal pain—Docetaxel—pancreatic cancer	9.6e-05	0.000788	CcSEcCtD
Valsartan—Vision blurred—Epirubicin—pancreatic cancer	9.46e-05	0.000777	CcSEcCtD
Valsartan—Alopecia—Doxorubicin—pancreatic cancer	9.43e-05	0.000774	CcSEcCtD
Valsartan—Mental disorder—Doxorubicin—pancreatic cancer	9.35e-05	0.000767	CcSEcCtD
Valsartan—Malnutrition—Doxorubicin—pancreatic cancer	9.29e-05	0.000763	CcSEcCtD
Valsartan—Flatulence—Doxorubicin—pancreatic cancer	9.15e-05	0.000751	CcSEcCtD
Valsartan—Dysgeusia—Doxorubicin—pancreatic cancer	9.1e-05	0.000747	CcSEcCtD
Valsartan—Vertigo—Epirubicin—pancreatic cancer	9.02e-05	0.00074	CcSEcCtD
Valsartan—Syncope—Epirubicin—pancreatic cancer	9e-05	0.000739	CcSEcCtD
Valsartan—Back pain—Doxorubicin—pancreatic cancer	8.99e-05	0.000738	CcSEcCtD
Valsartan—Hypersensitivity—Docetaxel—pancreatic cancer	8.95e-05	0.000735	CcSEcCtD
Valsartan—Muscle spasms—Doxorubicin—pancreatic cancer	8.93e-05	0.000733	CcSEcCtD
Valsartan—Palpitations—Epirubicin—pancreatic cancer	8.87e-05	0.000728	CcSEcCtD
Valsartan—Loss of consciousness—Epirubicin—pancreatic cancer	8.82e-05	0.000724	CcSEcCtD
Valsartan—Cough—Epirubicin—pancreatic cancer	8.76e-05	0.000719	CcSEcCtD
Valsartan—Vision blurred—Doxorubicin—pancreatic cancer	8.76e-05	0.000719	CcSEcCtD
Valsartan—Asthenia—Docetaxel—pancreatic cancer	8.72e-05	0.000715	CcSEcCtD
Valsartan—Pruritus—Docetaxel—pancreatic cancer	8.6e-05	0.000705	CcSEcCtD
Valsartan—Myalgia—Epirubicin—pancreatic cancer	8.55e-05	0.000702	CcSEcCtD
Valsartan—Chest pain—Epirubicin—pancreatic cancer	8.55e-05	0.000702	CcSEcCtD
Valsartan—Arthralgia—Epirubicin—pancreatic cancer	8.55e-05	0.000702	CcSEcCtD
Valsartan—Anxiety—Epirubicin—pancreatic cancer	8.52e-05	0.000699	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	8.49e-05	0.000697	CcSEcCtD
Valsartan—Dry mouth—Epirubicin—pancreatic cancer	8.36e-05	0.000686	CcSEcCtD
Valsartan—Vertigo—Doxorubicin—pancreatic cancer	8.35e-05	0.000685	CcSEcCtD
Valsartan—Syncope—Doxorubicin—pancreatic cancer	8.33e-05	0.000684	CcSEcCtD
Valsartan—Diarrhoea—Docetaxel—pancreatic cancer	8.31e-05	0.000682	CcSEcCtD
Valsartan—Palpitations—Doxorubicin—pancreatic cancer	8.21e-05	0.000674	CcSEcCtD
Valsartan—Oedema—Epirubicin—pancreatic cancer	8.19e-05	0.000673	CcSEcCtD
Valsartan—Anaphylactic shock—Epirubicin—pancreatic cancer	8.19e-05	0.000673	CcSEcCtD
Valsartan—Loss of consciousness—Doxorubicin—pancreatic cancer	8.17e-05	0.00067	CcSEcCtD
Valsartan—Infection—Epirubicin—pancreatic cancer	8.14e-05	0.000668	CcSEcCtD
Valsartan—Cough—Doxorubicin—pancreatic cancer	8.11e-05	0.000665	CcSEcCtD
Valsartan—Shock—Epirubicin—pancreatic cancer	8.06e-05	0.000662	CcSEcCtD
Valsartan—Nervous system disorder—Epirubicin—pancreatic cancer	8.04e-05	0.00066	CcSEcCtD
Valsartan—Dizziness—Docetaxel—pancreatic cancer	8.03e-05	0.000659	CcSEcCtD
Valsartan—Thrombocytopenia—Epirubicin—pancreatic cancer	8.02e-05	0.000659	CcSEcCtD
Valsartan—Skin disorder—Epirubicin—pancreatic cancer	7.96e-05	0.000653	CcSEcCtD
Valsartan—Chest pain—Doxorubicin—pancreatic cancer	7.91e-05	0.000649	CcSEcCtD
Valsartan—Myalgia—Doxorubicin—pancreatic cancer	7.91e-05	0.000649	CcSEcCtD
Valsartan—Arthralgia—Doxorubicin—pancreatic cancer	7.91e-05	0.000649	CcSEcCtD
Valsartan—Anxiety—Doxorubicin—pancreatic cancer	7.88e-05	0.000647	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	7.85e-05	0.000645	CcSEcCtD
Valsartan—Anorexia—Epirubicin—pancreatic cancer	7.81e-05	0.000641	CcSEcCtD
Valsartan—Dry mouth—Doxorubicin—pancreatic cancer	7.74e-05	0.000635	CcSEcCtD
Valsartan—Vomiting—Docetaxel—pancreatic cancer	7.72e-05	0.000634	CcSEcCtD
Valsartan—Rash—Docetaxel—pancreatic cancer	7.66e-05	0.000629	CcSEcCtD
Valsartan—Hypotension—Epirubicin—pancreatic cancer	7.66e-05	0.000628	CcSEcCtD
Valsartan—Dermatitis—Docetaxel—pancreatic cancer	7.65e-05	0.000628	CcSEcCtD
Valsartan—Headache—Docetaxel—pancreatic cancer	7.61e-05	0.000625	CcSEcCtD
Valsartan—Anaphylactic shock—Doxorubicin—pancreatic cancer	7.58e-05	0.000622	CcSEcCtD
Valsartan—Oedema—Doxorubicin—pancreatic cancer	7.58e-05	0.000622	CcSEcCtD
Valsartan—Infection—Doxorubicin—pancreatic cancer	7.53e-05	0.000618	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	7.47e-05	0.000613	CcSEcCtD
Valsartan—Shock—Doxorubicin—pancreatic cancer	7.46e-05	0.000612	CcSEcCtD
Valsartan—Nervous system disorder—Doxorubicin—pancreatic cancer	7.44e-05	0.00061	CcSEcCtD
Valsartan—Thrombocytopenia—Doxorubicin—pancreatic cancer	7.42e-05	0.000609	CcSEcCtD
Valsartan—Insomnia—Epirubicin—pancreatic cancer	7.41e-05	0.000608	CcSEcCtD
Valsartan—Skin disorder—Doxorubicin—pancreatic cancer	7.36e-05	0.000604	CcSEcCtD
Valsartan—Paraesthesia—Epirubicin—pancreatic cancer	7.36e-05	0.000604	CcSEcCtD
Valsartan—Dyspnoea—Epirubicin—pancreatic cancer	7.31e-05	0.0006	CcSEcCtD
Valsartan—Somnolence—Epirubicin—pancreatic cancer	7.28e-05	0.000598	CcSEcCtD
Valsartan—Anorexia—Doxorubicin—pancreatic cancer	7.23e-05	0.000593	CcSEcCtD
Valsartan—Nausea—Docetaxel—pancreatic cancer	7.22e-05	0.000592	CcSEcCtD
Valsartan—Dyspepsia—Epirubicin—pancreatic cancer	7.21e-05	0.000592	CcSEcCtD
Valsartan—Decreased appetite—Epirubicin—pancreatic cancer	7.12e-05	0.000585	CcSEcCtD
Valsartan—Hypotension—Doxorubicin—pancreatic cancer	7.08e-05	0.000581	CcSEcCtD
Valsartan—Gastrointestinal disorder—Epirubicin—pancreatic cancer	7.07e-05	0.000581	CcSEcCtD
Valsartan—Fatigue—Epirubicin—pancreatic cancer	7.06e-05	0.00058	CcSEcCtD
Valsartan—Constipation—Epirubicin—pancreatic cancer	7.01e-05	0.000575	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	6.91e-05	0.000567	CcSEcCtD
Valsartan—Insomnia—Doxorubicin—pancreatic cancer	6.86e-05	0.000563	CcSEcCtD
Valsartan—Paraesthesia—Doxorubicin—pancreatic cancer	6.81e-05	0.000559	CcSEcCtD
Valsartan—Dyspnoea—Doxorubicin—pancreatic cancer	6.76e-05	0.000555	CcSEcCtD
Valsartan—Somnolence—Doxorubicin—pancreatic cancer	6.74e-05	0.000553	CcSEcCtD
Valsartan—Gastrointestinal pain—Epirubicin—pancreatic cancer	6.7e-05	0.00055	CcSEcCtD
Valsartan—Dyspepsia—Doxorubicin—pancreatic cancer	6.67e-05	0.000548	CcSEcCtD
Valsartan—Decreased appetite—Doxorubicin—pancreatic cancer	6.59e-05	0.000541	CcSEcCtD
Valsartan—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	6.55e-05	0.000537	CcSEcCtD
Valsartan—Fatigue—Doxorubicin—pancreatic cancer	6.54e-05	0.000537	CcSEcCtD
Valsartan—Urticaria—Epirubicin—pancreatic cancer	6.51e-05	0.000534	CcSEcCtD
Valsartan—Constipation—Doxorubicin—pancreatic cancer	6.48e-05	0.000532	CcSEcCtD
Valsartan—Abdominal pain—Epirubicin—pancreatic cancer	6.48e-05	0.000532	CcSEcCtD
Valsartan—Gastrointestinal pain—Doxorubicin—pancreatic cancer	6.2e-05	0.000509	CcSEcCtD
Valsartan—Hypersensitivity—Epirubicin—pancreatic cancer	6.04e-05	0.000496	CcSEcCtD
Valsartan—Urticaria—Doxorubicin—pancreatic cancer	6.02e-05	0.000494	CcSEcCtD
Valsartan—Abdominal pain—Doxorubicin—pancreatic cancer	5.99e-05	0.000492	CcSEcCtD
Valsartan—Asthenia—Epirubicin—pancreatic cancer	5.88e-05	0.000483	CcSEcCtD
Valsartan—Pruritus—Epirubicin—pancreatic cancer	5.8e-05	0.000476	CcSEcCtD
Valsartan—Diarrhoea—Epirubicin—pancreatic cancer	5.61e-05	0.00046	CcSEcCtD
Valsartan—Hypersensitivity—Doxorubicin—pancreatic cancer	5.59e-05	0.000458	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—CCKAR—pancreatic cancer	5.49e-05	0.00181	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—IAPP—pancreatic cancer	5.44e-05	0.0018	CbGpPWpGaD
Valsartan—Asthenia—Doxorubicin—pancreatic cancer	5.44e-05	0.000446	CcSEcCtD
Valsartan—Dizziness—Epirubicin—pancreatic cancer	5.42e-05	0.000445	CcSEcCtD
Valsartan—AGTR1—Signaling Pathways—ZNRF3—pancreatic cancer	5.39e-05	0.00178	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ACVR1B—pancreatic cancer	5.39e-05	0.00178	CbGpPWpGaD
Valsartan—Pruritus—Doxorubicin—pancreatic cancer	5.36e-05	0.00044	CcSEcCtD
Valsartan—CYP2C9—Arachidonic acid metabolism—PTGS2—pancreatic cancer	5.3e-05	0.00175	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PTHLH—pancreatic cancer	5.22e-05	0.00173	CbGpPWpGaD
Valsartan—Vomiting—Epirubicin—pancreatic cancer	5.21e-05	0.000428	CcSEcCtD
Valsartan—Diarrhoea—Doxorubicin—pancreatic cancer	5.19e-05	0.000426	CcSEcCtD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	5.18e-05	0.00171	CbGpPWpGaD
Valsartan—Rash—Epirubicin—pancreatic cancer	5.17e-05	0.000424	CcSEcCtD
Valsartan—Dermatitis—Epirubicin—pancreatic cancer	5.16e-05	0.000424	CcSEcCtD
Valsartan—Headache—Epirubicin—pancreatic cancer	5.13e-05	0.000421	CcSEcCtD
Valsartan—Dizziness—Doxorubicin—pancreatic cancer	5.01e-05	0.000412	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—SHH—pancreatic cancer	5e-05	0.00165	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IAPP—pancreatic cancer	4.94e-05	0.00163	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ARG2—pancreatic cancer	4.88e-05	0.00161	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SSTR3—pancreatic cancer	4.88e-05	0.00161	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—DTX1—pancreatic cancer	4.88e-05	0.00161	CbGpPWpGaD
Valsartan—Nausea—Epirubicin—pancreatic cancer	4.87e-05	0.000399	CcSEcCtD
Valsartan—Vomiting—Doxorubicin—pancreatic cancer	4.82e-05	0.000396	CcSEcCtD
Valsartan—Rash—Doxorubicin—pancreatic cancer	4.78e-05	0.000392	CcSEcCtD
Valsartan—AGTR1—GPCR downstream signaling—SST—pancreatic cancer	4.78e-05	0.00158	CbGpPWpGaD
Valsartan—Dermatitis—Doxorubicin—pancreatic cancer	4.78e-05	0.000392	CcSEcCtD
Valsartan—Headache—Doxorubicin—pancreatic cancer	4.75e-05	0.00039	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—PTHLH—pancreatic cancer	4.74e-05	0.00157	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PTCH1—pancreatic cancer	4.74e-05	0.00157	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	4.68e-05	0.00155	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SSTR1—pancreatic cancer	4.68e-05	0.00155	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	4.6e-05	0.00152	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PPY—pancreatic cancer	4.59e-05	0.00152	CbGpPWpGaD
Valsartan—Nausea—Doxorubicin—pancreatic cancer	4.5e-05	0.00037	CcSEcCtD
Valsartan—AGTR1—Signaling Pathways—SSTR2—pancreatic cancer	4.5e-05	0.00149	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CNR1—pancreatic cancer	4.41e-05	0.00146	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCKBR—pancreatic cancer	4.35e-05	0.00144	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—SST—pancreatic cancer	4.34e-05	0.00143	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	4.32e-05	0.00143	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—pancreatic cancer	4.3e-05	0.00142	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	4.27e-05	0.00141	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TYMP—pancreatic cancer	4.27e-05	0.00141	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—GCG—pancreatic cancer	4.26e-05	0.00141	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNA5—pancreatic cancer	4.16e-05	0.00138	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—PIK3CA—pancreatic cancer	4.14e-05	0.00137	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—PTGS2—pancreatic cancer	4.12e-05	0.00136	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—DTX4—pancreatic cancer	4.09e-05	0.00135	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GLI1—pancreatic cancer	4.09e-05	0.00135	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	4.03e-05	0.00133	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CNR1—pancreatic cancer	4e-05	0.00132	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PPP2R5B—pancreatic cancer	3.98e-05	0.00131	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NRP1—pancreatic cancer	3.98e-05	0.00131	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PPP2R5B—pancreatic cancer	3.93e-05	0.0013	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—GCG—pancreatic cancer	3.87e-05	0.00128	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HEY2—pancreatic cancer	3.83e-05	0.00127	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PRSS1—pancreatic cancer	3.78e-05	0.00125	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GAST—pancreatic cancer	3.74e-05	0.00124	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	3.7e-05	0.00122	CbGpPWpGaD
Valsartan—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—pancreatic cancer	3.61e-05	0.00119	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SCT—pancreatic cancer	3.54e-05	0.00117	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HEY1—pancreatic cancer	3.54e-05	0.00117	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	3.52e-05	0.00116	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—VEGFA—pancreatic cancer	3.5e-05	0.00116	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—pancreatic cancer	3.5e-05	0.00116	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GLP1R—pancreatic cancer	3.44e-05	0.00114	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	3.43e-05	0.00113	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—DPYD—pancreatic cancer	3.38e-05	0.00112	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCK—pancreatic cancer	3.38e-05	0.00112	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—pancreatic cancer	3.34e-05	0.0011	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CNR2—pancreatic cancer	3.29e-05	0.00109	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GLP1R—pancreatic cancer	3.29e-05	0.00109	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—CXCL8—pancreatic cancer	3.29e-05	0.00109	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ARG2—pancreatic cancer	3.28e-05	0.00108	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCKAR—pancreatic cancer	3.24e-05	0.00107	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—TGFB1—pancreatic cancer	3.22e-05	0.00106	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—SLC2A2—pancreatic cancer	3.21e-05	0.00106	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	3.18e-05	0.00105	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JAG2—pancreatic cancer	3.14e-05	0.00104	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MEN1—pancreatic cancer	3.1e-05	0.00102	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TP53—pancreatic cancer	3.09e-05	0.00102	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	3.07e-05	0.00101	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—pancreatic cancer	3.06e-05	0.00101	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SHH—pancreatic cancer	2.96e-05	0.000977	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH4—pancreatic cancer	2.94e-05	0.000971	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IAPP—pancreatic cancer	2.92e-05	0.000965	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TYMP—pancreatic cancer	2.87e-05	0.000948	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTHLH—pancreatic cancer	2.8e-05	0.000926	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTCH1—pancreatic cancer	2.8e-05	0.000926	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.79e-05	0.000923	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—pancreatic cancer	2.78e-05	0.00092	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	2.63e-05	0.00087	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CG—pancreatic cancer	2.6e-05	0.000859	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—EGF—pancreatic cancer	2.57e-05	0.000849	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SST—pancreatic cancer	2.56e-05	0.000847	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CG—pancreatic cancer	2.53e-05	0.000836	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JAG1—pancreatic cancer	2.51e-05	0.000829	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH3—pancreatic cancer	2.5e-05	0.000826	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CD44—pancreatic cancer	2.49e-05	0.000822	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.43e-05	0.000805	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.41e-05	0.000797	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GCG—pancreatic cancer	2.38e-05	0.000788	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	2.36e-05	0.000782	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CNR1—pancreatic cancer	2.36e-05	0.000782	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CD44—pancreatic cancer	2.35e-05	0.000778	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GLP1R—pancreatic cancer	2.31e-05	0.000764	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CG—pancreatic cancer	2.3e-05	0.000759	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CD—pancreatic cancer	2.28e-05	0.000755	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GCG—pancreatic cancer	2.28e-05	0.000755	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNA1—pancreatic cancer	2.28e-05	0.000754	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—DPYD—pancreatic cancer	2.27e-05	0.000751	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—STK11—pancreatic cancer	2.24e-05	0.000741	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CD—pancreatic cancer	2.22e-05	0.000735	CbGpPWpGaD
Valsartan—ALB—Metabolism—PRSS1—pancreatic cancer	2.16e-05	0.000714	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC2A2—pancreatic cancer	2.16e-05	0.000713	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STK11—pancreatic cancer	2.15e-05	0.00071	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	2.13e-05	0.000706	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IFNA2—pancreatic cancer	2.12e-05	0.000701	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.1e-05	0.000695	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.06e-05	0.000681	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CD—pancreatic cancer	2.02e-05	0.000667	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CB—pancreatic cancer	1.99e-05	0.000658	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CB—pancreatic cancer	1.94e-05	0.00064	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TYMS—pancreatic cancer	1.93e-05	0.000637	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SMAD4—pancreatic cancer	1.88e-05	0.000622	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.88e-05	0.00062	CbGpPWpGaD
Valsartan—ALB—Metabolism—ARG2—pancreatic cancer	1.87e-05	0.000619	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—CXCL8—pancreatic cancer	1.86e-05	0.000615	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HES1—pancreatic cancer	1.84e-05	0.000607	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PRSS1—pancreatic cancer	1.77e-05	0.000585	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.76e-05	0.000581	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CXCL8—pancreatic cancer	1.69e-05	0.000559	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CD44—pancreatic cancer	1.67e-05	0.000552	CbGpPWpGaD
Valsartan—ALB—Metabolism—TYMP—pancreatic cancer	1.64e-05	0.000541	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.64e-05	0.000541	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.62e-05	0.000536	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TERT—pancreatic cancer	1.61e-05	0.000532	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GCG—pancreatic cancer	1.6e-05	0.000529	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	1.6e-05	0.000528	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOE—pancreatic cancer	1.57e-05	0.000518	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	1.55e-05	0.000514	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HIF1A—pancreatic cancer	1.54e-05	0.000509	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TSC2—pancreatic cancer	1.54e-05	0.000508	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ARG2—pancreatic cancer	1.53e-05	0.000507	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLAU—pancreatic cancer	1.51e-05	0.000498	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—STK11—pancreatic cancer	1.51e-05	0.000498	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOE—pancreatic cancer	1.5e-05	0.000497	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.48e-05	0.000491	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KDR—pancreatic cancer	1.47e-05	0.000487	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	1.43e-05	0.000472	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CG—pancreatic cancer	1.41e-05	0.000468	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.41e-05	0.000467	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NFKBIA—pancreatic cancer	1.4e-05	0.000463	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOTCH1—pancreatic cancer	1.39e-05	0.000458	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—pancreatic cancer	1.37e-05	0.000451	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CG—pancreatic cancer	1.36e-05	0.000448	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—NRAS—pancreatic cancer	1.36e-05	0.000448	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.35e-05	0.000447	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TYMP—pancreatic cancer	1.34e-05	0.000443	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGF—pancreatic cancer	1.34e-05	0.000443	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CG—pancreatic cancer	1.34e-05	0.000443	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EGF—pancreatic cancer	1.32e-05	0.000438	CbGpPWpGaD
Valsartan—ALB—Metabolism—GLP1R—pancreatic cancer	1.32e-05	0.000436	CbGpPWpGaD
Valsartan—ALB—Metabolism—DPYD—pancreatic cancer	1.3e-05	0.000429	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TYMS—pancreatic cancer	1.3e-05	0.000428	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CD—pancreatic cancer	1.24e-05	0.000411	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—pancreatic cancer	1.24e-05	0.000408	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC2A2—pancreatic cancer	1.23e-05	0.000407	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.22e-05	0.000403	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	1.21e-05	0.000401	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CD—pancreatic cancer	1.19e-05	0.000394	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.18e-05	0.00039	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CD—pancreatic cancer	1.18e-05	0.000389	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.18e-05	0.000389	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—KRAS—pancreatic cancer	1.17e-05	0.000386	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.11e-05	0.000366	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CB—pancreatic cancer	1.08e-05	0.000358	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GLP1R—pancreatic cancer	1.08e-05	0.000357	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—pancreatic cancer	1.07e-05	0.000355	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.07e-05	0.000354	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CA—pancreatic cancer	1.07e-05	0.000354	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—DPYD—pancreatic cancer	1.06e-05	0.000351	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOE—pancreatic cancer	1.05e-05	0.000348	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CB—pancreatic cancer	1.04e-05	0.000343	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CB—pancreatic cancer	1.03e-05	0.000339	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	1.01e-05	0.000333	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—pancreatic cancer	9.98e-06	0.00033	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	9.98e-06	0.00033	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	9.97e-06	0.00033	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—HRAS—pancreatic cancer	9.92e-06	0.000328	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	9.92e-06	0.000328	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—pancreatic cancer	9.64e-06	0.000319	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	9.63e-06	0.000319	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CASP3—pancreatic cancer	9.55e-06	0.000316	CbGpPWpGaD
Valsartan—ALB—Metabolism—CD44—pancreatic cancer	9.54e-06	0.000316	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CG—pancreatic cancer	9.51e-06	0.000314	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTEN—pancreatic cancer	9.37e-06	0.00031	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	9.34e-06	0.000309	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCND1—pancreatic cancer	9.3e-06	0.000308	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	9.26e-06	0.000306	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CTNNB1—pancreatic cancer	9.21e-06	0.000305	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—pancreatic cancer	9.17e-06	0.000303	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCG—pancreatic cancer	9.15e-06	0.000302	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—pancreatic cancer	9.03e-06	0.000299	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTEN—pancreatic cancer	8.98e-06	0.000297	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	8.77e-06	0.00029	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—pancreatic cancer	8.76e-06	0.00029	CbGpPWpGaD
Valsartan—ALB—Metabolism—STK11—pancreatic cancer	8.6e-06	0.000284	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CD—pancreatic cancer	8.36e-06	0.000276	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SRC—pancreatic cancer	8.32e-06	0.000275	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SRC—pancreatic cancer	8.23e-06	0.000272	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—pancreatic cancer	8.11e-06	0.000268	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.07e-06	0.000267	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—pancreatic cancer	8.03e-06	0.000265	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—pancreatic cancer	8.01e-06	0.000265	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NRAS—pancreatic cancer	8.01e-06	0.000265	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NRAS—pancreatic cancer	7.91e-06	0.000262	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CD44—pancreatic cancer	7.81e-06	0.000258	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	7.65e-06	0.000253	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	7.58e-06	0.000251	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCG—pancreatic cancer	7.49e-06	0.000248	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—pancreatic cancer	7.46e-06	0.000247	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—pancreatic cancer	7.44e-06	0.000246	CbGpPWpGaD
Valsartan—ALB—Metabolism—TYMS—pancreatic cancer	7.4e-06	0.000245	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—pancreatic cancer	7.35e-06	0.000243	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—pancreatic cancer	7.3e-06	0.000241	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CB—pancreatic cancer	7.28e-06	0.000241	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—pancreatic cancer	7.22e-06	0.000239	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—STK11—pancreatic cancer	7.04e-06	0.000233	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KRAS—pancreatic cancer	6.89e-06	0.000228	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KRAS—pancreatic cancer	6.81e-06	0.000225	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.61e-06	0.000219	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CA—pancreatic cancer	6.61e-06	0.000218	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CA—pancreatic cancer	6.33e-06	0.000209	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTEN—pancreatic cancer	6.29e-06	0.000208	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CA—pancreatic cancer	6.26e-06	0.000207	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—pancreatic cancer	6.13e-06	0.000203	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TYMS—pancreatic cancer	6.06e-06	0.0002	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—pancreatic cancer	6.05e-06	0.0002	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOE—pancreatic cancer	6.02e-06	0.000199	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HRAS—pancreatic cancer	5.86e-06	0.000194	CbGpPWpGaD
Valsartan—ALB—Hemostasis—HRAS—pancreatic cancer	5.79e-06	0.000191	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.7e-06	0.000188	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CG—pancreatic cancer	5.43e-06	0.00018	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—pancreatic cancer	5.4e-06	0.000178	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—pancreatic cancer	5.24e-06	0.000173	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—pancreatic cancer	5.17e-06	0.000171	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—pancreatic cancer	5.11e-06	0.000169	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOE—pancreatic cancer	4.93e-06	0.000163	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CD—pancreatic cancer	4.77e-06	0.000158	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.66e-06	0.000154	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	4.45e-06	0.000147	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CA—pancreatic cancer	4.44e-06	0.000147	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—pancreatic cancer	4.29e-06	0.000142	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CB—pancreatic cancer	4.16e-06	0.000138	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—pancreatic cancer	4.12e-06	0.000136	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	3.91e-06	0.000129	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—pancreatic cancer	3.63e-06	0.00012	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTEN—pancreatic cancer	3.6e-06	0.000119	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	3.41e-06	0.000113	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—pancreatic cancer	3.38e-06	0.000112	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTEN—pancreatic cancer	2.94e-06	9.73e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CA—pancreatic cancer	2.54e-06	8.39e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	2.08e-06	6.87e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—pancreatic cancer	2.07e-06	6.85e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—pancreatic cancer	1.7e-06	5.61e-05	CbGpPWpGaD
